gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cytochrome P450, family 2, subfamily D, polypeptide 6

CYP2D6, cytochrome P450 2D6
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 20% of commonly prescribed drugs. Its substrates include debrisoquine, an adrenergic-blocking drug; sparteine and propafenone, both anti-arrythmic drugs; and amitryptiline, an anti-depressant. The gene is highly polymorphic in the population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. The gene is located near two cytochrome P450 pseudogenes on chromosome 22q13.1. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CYP3A4, Cyp, CYP2C19, CYP1A1, CYP2C9
Papers on CYP2D6
Genetic polymorphism of CYP2D6 in patients with systemic lupus erythematosus and systemic sclerosis.
New
Waszczykowska et al., Łódź, Poland. In Autoimmunity, Feb 2016
The aim of the study was to evaluate the CYP2D6 polymorphism in the SLE (systemic lupus erythematosus) and SSc (systemic sclerosis) patients and to investigate a possible correlation with disease susceptibility.
Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
New
Sukasem et al., Bangkok, Thailand. In J Child Adolesc Psychopharmacol, Feb 2016
OBJECTIVE: The purpose of this study was to investigate the influence of CYP2D6 gene polymorphisms on plasma concentrations of risperidone and its metabolite in Thai children and adolescents with autism spectrum disorder (ASD).
ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes.
New
Mashimo et al., Kyoto, Japan. In Nat Commun, Dec 2015
Finally, three gRNAs and two ssODNs replace 58-kb of the rat Cyp2d cluster with a 6.2-kb human CYP2D6 gene.
Interaction of the CYP1A1 gene polymorphism and smoking in non-small cell lung cancer susceptibility.
New
Liu et al., Jingmen, China. In Genet Mol Res, Dec 2015
Currently, most research has investigated the GSTM1, XRCC1, XRCC3, CYP2D6, and C188T genes.
Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.
Review
New
LLerena et al., Badajoz, Spain. In Pharmacogenomics J, Nov 2015
Regarding CYP2C19 metabolic phenotype, poor metabolizers (PMs) were more frequent among Asians than in Europeans, contrarily to the phenomenon reported for CYP2D6.
Eliglustat: A Review in Gaucher Disease Type 1.
Review
New
Scott, Auckland, New Zealand. In Drugs, Sep 2015
In the meantime, with its convenient oral regimen, eliglustat is an emerging alternative therapy to ERT for the long-term treatment of adults with GD1 who are CYP2D6 EMs, IMs or PMs.
Effect of acute paraquat poisoning on CYP450 isoforms activity in rats by cocktail method.
Ma et al., Lishui, China. In Int J Clin Exp Med, 2014
The influence of acute paraquat poisoning on the activities of CYP450 isoforms CYP2B6, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP2C19 were evaluated by cocktail method, they were responded by the changes of pharmacokinetic parameters of bupropion, phenacetin, tolbutamide, metoprolol, midazolam and omeprazole.
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Review
Turcotte et al., Jackson, United States. In Drug Des Devel Ther, 2014
The dose of eliglustat is 84 mg twice a day or once daily depending on the cytochrome P450 2D6 genotype of the patient.
[Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].
Review
Krupitsky et al., In Zh Nevrol Psikhiatr Im S S Korsakova, 2014
However, evidence base while does not allow to do the significant prognosis of development of EPS based on genetic testing of CYP2D6 and CYP7A2 polymorphisms.
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Review
Bishop et al., Duluth, United States. In Pharmacogenomics, 2014
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder and is predominantly metabolized by the CYP2D6 enzyme.
Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
GeneRIF
Scott et al., Lawrence, United States. In J Biol Chem, 2012
Although both the hepatic CYP2A6 and respiratory CYP2A13 enzymes metabolize these compounds, CYP2A13 does so with much higher catalytic efficiency, but the structural basis for this has been unclear
Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.
GeneRIF
Cuzick et al., London, United Kingdom. In Br J Cancer, 2012
Data from the preventive IBIS-I study did not support an association between the CYP2D6 phenotype and breast cancer outcome.
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
GeneRIF
Adithan et al., Pondicherry, India. In Cancer Chemother Pharmacol, 2012
Data suggest that reduced CYP2D6 activity is associated with poor treatment outcomes, in terms of increased risk of recurrence and shorter recurrence free survival, in breast cancer patients on adjuvant tamoxifen therapy.
Cytochrome P450 2D6 polymorphism is a molecular genetic marker of liver cirrhosis progression.
GeneRIF
Lyakhovich et al., Novosibirsk, Russia. In Bull Exp Biol Med, 2012
There is an association between CYP2D6 (1846G/A) genotype and rapid liver cirrhosis development.
Significance of genetic polymorphism of CYP2D6 in the pathogenesis of systemic sclerosis.
GeneRIF
Skrętkowicz et al., Łódź, Poland. In Pharmacol Rep, 2011
The obtained results may suggest the influence of CYP2D6*4 gene mutated alleles on increased incidence of systemic sclerosis.
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Impact
Carey et al., Chapel Hill, United States. In J Clin Oncol, 2011
PURPOSE: We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism.
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Impact
Mathijssen et al., Rotterdam, Netherlands. In J Clin Oncol, 2011
PURPOSE: Tamoxifen, a widely used agent for the prevention and treatment of breast cancer, is mainly metabolized by CYP2D6 and CYP3A to form its most abundant active metabolite, endoxifen.
Germline genetic variation, cancer outcome, and pharmacogenetics.
Review
Impact
Liu et al., Toronto, Canada. In J Clin Oncol, 2010
Putative germline pharmacogenetic predictors of outcome include DPYD polymorphisms and fluorouracil toxicity, UGT1A1 variation and irinotecan toxicity, and CYP2D6 polymorphisms and tamoxifen efficacy, with emerging data on predictors of molecularly targeted or biologic drugs.
Coprescription of tamoxifen and medications that inhibit CYP2D6.
Review
Impact
Goetz et al., Rochester, United States. In J Clin Oncol, 2010
Evidence has emerged that the clinical benefit of tamoxifen is related to the functional status of the hepatic metabolizing enzyme cytochrome P450 2D6 (CYP2D6).
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Impact
GeneRIF
Guchelaar et al., Leiden, Netherlands. In J Clin Oncol, 2010
This observational study did not show an association between concomitant CYP2D6 inhibitor use and breast cancer recurrence among patients treated with adjuvant tamoxifen.
share on facebooktweetadd +1mail to friends